TMRW Job Title: Corporate Controller
ABOUT THE COMPANY
TMRW is building a fully integrated hardware and software platform which will guide the conception of ~300M people in coming decades. The TMRW platform provides the world's first automated digital and robotic cryo- management system for in vitro fertilization (IVF) clinics, featuring RFID-enabled digital chain of custody for all fertility tissues. TMRW reduces human error, increases efficiency and enhances clinical outcomes.
The Corporate Controller will play a critical role in all financial and accounting activities at TMRW. Key responsibilities will include analysis of budget versus actuals, payroll forecasting, accounts payable, accounts receivable and financial reporting.
The candidate will be responsible for managing product implementation and data migration over from existing financial software to an ERP, as well as ongoing day-to-day system usage. The candidate will also lead system training for relevant TMRW employees and actively seek out additional accounting platforms to improve efficiencies.
TMRW's business has a recurring SaaS revenue model. Though initially TMRW's clinical partners will be the party billing consumers, it is likely that TMRW will eventually assume responsibility for billing patients on behalf of our clinical partners, with a focus on reducing churn and improving lifetime values. The Corporate Controller will play an important role in executing this likely transition.
The ideal candidate will be a self-motivated, strategic individual with 5-10 years of managerial accounting and financial management experience in a start-up environment. In addition, the candidate must be passionate about international accounting, financial systems, internal controls and be able to partner with our CFO and FP&A team.
KEY DUTIES AND RESPONSIBILITIES
ABOUT IN VITRO FERTILIZATION (IVF)
It's becoming increasingly apparent that fertility medicine represents one of the triumphs of the last 50-years of medical history. Today, one in 20 children born in Japan is the result of IVF. In Norway, the number is one in 10.
Powerful, irreversible scientific and demographic forces are driving this development. Today the advantages of involving a fertility doctor in the process of conceiving a child are numerous—and growing rapidly. For women, it allows them to better safeguard their fertility over a longer period of time. For all would-be parents, a growing list of devastating, often fatal genetic conditions (Tay Sachs, Sickle Cell Anemia, Cystic Fibrosis) can be screened against and easily avoided, affording the opportunity to end certain disease states within a generation. All of these advances are linked to the newly perfected technology of vitrification, the fast freezing of human embryos and oocytes (eggs).
As the advantages of vitrification mount, IVF is quickly becoming a "freeze all" clinical practice requiring both long- term and short term cryostorage in the next decade for millions of patients, up from only 5,000 just a few years ago.
The existing cryostorage infrastructure in medical clinics can no longer accommodate this growing demand.
ABOUT THE FOUNDERS
TMRW's three co-founders—Joshua Abram, Alan Murray and Jeff Port—are serial entrepreneurs who have founded and led firms involved in diverse fields including data and analytics, medical consumables and hospitality. Prior to founding TMRW, Joshua and Alan—operating through Coriolis Ventures—founded and served as Co-CEOs of several venture-backed companies at the intersection of data, machine learning and marketing. These companies today employ approximately 1,000 people, mostly in Manhattan, and routinely process tens of billions of data events every 24 hours.
While building these technology companies, Joshua and Alan also made significant commitment to founding and/or providing the earliest seed funding to firms that spoke to their shared interest in hospitality and innovative, commercial and saleable luxury experiences. They co-founded Integral Ad Science, a Marketing Technology company focused on advertisement effectiveness solutions, which they recently sold to Vista Equity Partners. Additionally, Joshua and Alan co-founded the paradigm shifting NeueHouse, which brought the amenities and sensibility of a boutique hotel to the office environment and was widely celebrated for, as Departure Magazine wrote, fundamentally changing "what one might aspire to in a utopian, perfected office." Joshua and Alan also provided the earliest seed funding to Alice, a hospitality technology company automating the guest experience at leading hotels which later received $30 million in funding from Expedia. Jeff Port is thoracic surgeon who, while practicing and teaching full-time at Weill Cornell
Medical Center, founded RF Surgical which developed a now widely used technology to track items used by surgeons during complex operation to assure that nothing was left behind after wound closure. Companies founded by the
TMRW principals have enjoyed exits totaling over $1 billion.
Job Type: Full-time